Jun
2026
Shanghai New International Expo Center
Visit us
stand E3A28, Finished Dosage
Zone

Shanxi Zhendong Pharmaceutical Co., Ltd.

About Us

Zhendong Group was founded on October 1, 1993, the National Day of China, representing the original aspiration of growing large together with the country. Zhendong started with the petroleum trade and became the top one in the private sector nationwide within 7 years. In 2002, it transformed into the pharmaceutical industry and established the first company listed on the GEM in Shanxi Province within 8 years. The group has 8 major industrial enterprises, 32 subsidiaries and 4 major R&D platforms covering four major sectors: Chinese and Western Pharmaceuticals, Health Functional Foods, Health Care Products, and Chinese Medicinal Materials Planting. It has gained food safety HACCP certification, the international CNAS certification, is honored as “National Innovative Demonstration Enterprise”, “National Patent Pilot Enterprise”, “National Intellectual Property Advanced Enterprise”, and “International Joint Research Demonstration Enterprise, et al. Zhendong strives to forge Shanxi Brand, China Brand, and International Brand, actively undertaking social responsibilities, making contributions to society and country!

  • Country/Region:
    China
  • On CPHI since:
    2017
Contact info
  • ZHENDONG SCIENCE PARK, GUANGMING SOUTH ROAD, CHANGZHI COUNTY, 047100, SHANXI PROVINCE, Beijing, China
Event information
CPHI & PMEC China 2026
  • 16 Jun 2026 - 18 Jun 2026
  • Shanghai New International Expo Center
  • Visit us at stand E3A28, Finished Dosage

Products Featured at CPHI & PMEC China 2026

  • Abiraterone acetate tablets

    Product Abiraterone acetate tablets

    Abiraterone works by reducing androgen production in the body. Androgens are male hormones that can promote tumor growth in the prostate gland.


    Abiraterone is used together with steroid medication (prednisone or methylprednisolone) to treat prostate cancer that has spread to o...
  • Bicalutamide capsules

    Product Bicalutamide capsules

    50mg daily: Combination with luteinizing hormone releasing hormone (LHRH) analogs or surgical orchiectomy for the treatment of advanced prostatic carcinoma.

    150mg daily: For the treatment of patients with locally advanced prostate cancer without distant metastasis, who are unsuitable or unwillin...
  • Enzalutamide Soft Capsules

    Product Enzalutamide Soft Capsules

    Suitable for metastatic resistance to prostate cancer (CRPC). After the failure of androgen deprivation of therapy (ADT), Enzalutamide can delay the progress of the disease by inhibiting the inhibitors of therogen receptor signaling pathway and improve the quality of life of patients.